ATAGI met on 12 May 2021 to review the latest developments relating to the AstraZeneca COVID-19 vaccine and Thrombosis and Thrombocytopenia Syndrome (TTS) cases in Australia and overseas.
ATAGI considered the current status of TTS cases in Australia including confirmed and probable cases. The latest TGA statement on TTS cases can be found here.
ATAGI, in collaboration with experts from the Thrombosis and Haemostasis Society of Australia and New Zealand, reviewed Australian coverage data and TTS rate analysis and considered the different patterns and spectrum of TTS cases in Australia. International data including the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and Joint Committee on Vaccination and Immunisation (JCVI) recommendation on the use of AstraZeneca COVID-19 vaccine for people aged under 40 was also considered.
At this time, there is no update to the ATAGI statement from 23 April 2021 in relation to the use of the AstraZeneca COVID-19 vaccine.
ATAGI continue to be regularly updated by the TGA on the TTS cases under investigation in Australia and will meet weekly to utilise both confirmed and probable TTS case rates and international data to inform recommendations for AstraZeneca COVID-19 vaccine use and will provide updated advice as/when further information becomes available.
ATAGI understands that of the cases of TTS confirmed by the TGA, all patients, with the exception of sadly one fatality, are recovering and are stable.